As a global leader in structural heart diseases, Edwards Lifesciences strongly supports the objectives of the EU Public Procurement Directive to improve quality access to healthcare technologies. After more than 10 years of application, and many challenges in its rightful execution, the revision of the EU Directive on Public Procurement provides an important opportunity to ensure that breakthrough implantable…
EL
Edwards Lifesciences
Company · Switzerland · EU Transparency Register 908457634413-95
13
positions filed
in the 665 files tracked
12
legislative files
of 665 tracked
11
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #99 by legislative files engaged, a count of participation, not a measure of influence.
1.2
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2019
in the register since
Declares membership of
- MedTech Europe →
- Friends of Europe
- AmCham EU
- European Patient Safety Foundation
- EU Structural Heart Disease Coalition →
- Informal Working Group on Capacity-Enhancing Innovations
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Head office
- Dilbeek, Belgium
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Edwards in PolicySpeak: request access →
Work at Edwards Lifesciences? so we know who speaks for it.
Their record over time
Edwards Lifesciences filed 13 positions between 2 Feb 2021 and 19 May 2026, across 12 of the 665 legislative files tracked here, attaching a full position paper 11 times.
2021 · 4 filed2022 · 1 filed2023 · 2 filed2025 · 4 filed2026 · 2 filed
What they argued
As a global leader in structural heart diseases, Edwards Lifesciences strongly supports the objectives of the EU Public Procurement Directive to improve quality access to healthcare technologies. After more than 10 years of application, and many challenges in its rightful execution, the revision of the EU Directive on Public Procurement provides an important opportunity to ensure that breakthrough implantable…
Edwards Lifesciences, a global leader in breakthrough structural heart innovations investing 19% of annual revenues in breakthrough research & innovation, strongly welcomes the upcoming reform of the EU Medical Device Regulation process.
Edwards Lifesciences a global leader in structural heart innovations - welcomes the EU commitment to health and innovation as strategic priorities in the next MFF, and specifically the EU Fund for Competitiveness which has the potential to boost access to, and deployment of, breakthrough innovation, supporting Europe leadership in innovation, whilst strengthening population' health.
As a global leader in medical technology innovations for structural heart disease, critical care, and surgical monitoring, Edwards Lifesciences is committed to addressing unmet healthcare needs and improving patient outcomes.
Edwards Lifesciences welcomes the proposal for the European Innovation Act as a timely and strategic initiative to accelerate the uptake of breakthrough innovation and strengthen Europes industrial competitiveness.
Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives.
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring for critically ill patients. More specifically, for the management of critically ill patients, Edwards Lifesciences develops predictive monitoring solutions.
The recently adopted European Union Cardiovascular Health Safe Hearts Plan represents a critical step forward to tackle the burden of Europes leading cause of death, cardiovascular disease (CVD), including Structural Heart Disease (SHD).
With the proposal for a Regulation (2023/0005) submitted on January 6, 2023 extending the transition period of the EU regulations on medical devices, the European Commission is working to ensure smooth implementation of its regulatory framework for medical devices, ensuring their availability, safety and effectiveness.
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring for critically ill patients. We welcome the EU Commission’s initiative strengthen the mandate of the European Centre for Disease Control and Prevention (ECDC).
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring for critically ill patients. Edwards Lifesciences EMEACLA welcomes the EU Commission’s initiative to strengthen the role of the European Medicines Agency (EMA) to better address public health emergencies.
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring for critically ill patients. We welcome the EU Commission’s initiative update current rules on serious cross-border health threats to health.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Edwards Lifesciences next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 370.
Is this your organization?
Everything on this page comes from Edwards Lifesciences’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.